A federal outside panel voted Thursday to relax rules on seven peptides, including BPC-157 and TB-500. The vote was tight. It is not final. The FDA has given no word on whether it will take up the recommendation. The move came after weeks of stakeholder sessions. Wellness backers advocated aggressively for wider access. RFK Jr. was among them. Critics say these compounds have little hard evidence of safety or help for most uses. The call could alter how the agency handles a part of the wellness market that is surging ahead. Market observers are watching to see if the regulator moves in step. A spokesperson for the regulator offered no firm timeline for a response. Industry voices argue the change would open up access to substances users swear by. Health groups warn that looser rules could invite misuse across a wide-open market. The panel vote only lays the groundwork for change, and the final call rests with the federal regulator.